Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer

• Published in: PLoS pathogens 2022-11, Vol.18 (11), p.e1010945
• Main Authors: van Schooten, Jelle, Schorcht, Anna, Farokhi, Elinaz, Umotoy, Jeffrey C, Gao, Hongmei, van den Kerkhof, Tom L G M, Dorning, Jessica, Rijkhold Meesters, Tim G, van der Woude, Patricia, Burger, Judith A, Bijl, Tom, Ghalaiyini, Riham, Torrents de la Peña, Alba, Turner, Hannah L, Labranche, Celia C, Stanfield, Robyn L, Sok, Devin, Schuitemaker, Hanneke, Montefiori, David C, Burton, Dennis R, Ozorowski, Gabriel, Seaman, Michael S, Wilson, Ian A, Sanders, Rogier W, Ward, Andrew B, van Gils, Marit J
• Format: Article
• Language: English
• Subjects: AIDS vaccines; Animals; Antibodies; Antibodies, Monoclonal; Antigenic determinants; Biology and Life Sciences; Broadly Neutralizing Antibodies; Cryoelectron Microscopy; Engineering and Technology; Genetic aspects; Health aspects; HIV Envelope Protein gp120; HIV infection; HIV Seropositivity; HIV-1; Identification and classification; Immunological research; Medicine and Health Sciences; Microbiology; Parasitology; Prevention; Research and Analysis Methods; Viral antibodies; Virology
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1010945

Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subtypes and are able to prevent HIV-1 infection in animal models. However, bNAbs are extremely difficult to induce by vaccination. Defining the developmental pathways towards neutralization breadth can assist in the design of strategies to elicit protective bNAb responses by vaccination. Here, HIV-1 envelope glycoproteins (Env)-specific IgG+ B cells were isolated at various time points post infection from an HIV-1 infected elite neutralizer to obtain monoclonal antibodies (mAbs). Multiple antibody lineages were isolated targeting distinct epitopes on Env, including the gp120-gp41 interface, CD4-binding site, silent face and V3 region. The mAbs each neutralized a diverse set of HIV-1 strains from different clades indicating that the patient's remarkable serum breadth and potency might have been the result of a polyclonal mixture rather than a single bNAb lineage. High-resolution cryo-electron microscopy structures of the neutralizing mAbs (NAbs) in complex with an Env trimer generated from the same individual revealed that the NAbs used multiple strategies to neutralize the virus; blocking the receptor binding site, binding to HIV-1 Env N-linked glycans, and disassembly of the trimer. These results show that diverse NAbs can complement each other to achieve a broad and potent neutralizing serum response in HIV-1 infected individuals. Hence, the induction of combinations of moderately broad NAbs might be a viable vaccine strategy to protect against a wide range of circulating HIV-1 viruses.